GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

rontalizumab   Click here for help

GtoPdb Ligand ID: 9640

Synonyms: 9F3v13 | RhuMAB IFNalpha | rhuMAb interferon-α
Immunopharmacology Ligand
Compound class: Antibody
Comment: Rontalizumab is a humanized monoclonal antibody targeting interferon alpha (IFNα) that has immunomodulatory potential. It was humanized from a mouse monoclonal as described in [2], and peptide sequences of the antibody (identified as humanized 9F3v13) are claimed in Genentech patent US7582445 [1].
Rontalizumab is functionally similar to sifalimumab. Development of both of these anti-IFNα agents has been discontinued. Compare these with anifrolumab, which targets the type I interferon receptor (IFNAR1) rather than the ligand itself, and which has progressed to Phase 3 clinical trial.
A 3D X-ray structure of rontalizumab's Fab domain bound to IFNα2 has been published (PDB identifier 4Z5R) [5].
Immunopharmacology Comments
The rationale for targeting IFNα in SLE, and outcomes from anti-IFNα or anti-type I interferon receptor (IFNAR1) antibody therapies in SLE patients is discussed by Kalunian (2016) [3].
Immunopharmacology Disease
Disease X-Refs Comment References
Systemic lupus erythematosus Disease Ontology: DOID:9074
OMIM: 152700
Orphanet: ORPHA536
 Failed Phase 2 clinical candidate for SLE.